InvestorsHub Logo

2014shelby

01/30/21 8:11 AM

#23414 RE: LT 1990 #23411

Thanks for your thoughts and summary. GLTA shareholders

Gatorca

01/30/21 10:22 AM

#23420 RE: LT 1990 #23411

That was a great find by RIO last night LT :-)

knrorrel

01/31/21 12:51 AM

#23431 RE: LT 1990 #23411

great , sounds very good , what do you think we can count on FDA news? (until Summer? or earlier?)

Risk

01/31/21 8:03 AM

#23439 RE: LT 1990 #23411

Thanks for sharing !

Gatorca

01/31/21 1:11 PM

#23449 RE: LT 1990 #23411

The development of a useful therapeutic treatment for COVID-19 would be substantial. As a low-market cap, non-vaccine COVID-19 therapeutic company currently undergoing a Phase 3 trial, Revive executives believe the company has strong growth potential as its Bucillamine trial meets safety and efficacy endpoints.
Just wanted to repost the USA Today News for any new investors :-)

https://www.usatoday.com/story/sponsor-story/imperium-group/2021/01/25/revive-therapeutics-phase-3-clinical-trial-covid-19-treatment/6672439002/

vortmaximum

02/01/21 6:14 AM

#23473 RE: LT 1990 #23411

I like this scenario and certainly a possibility. RVVTF